Translation of "use procedures " (English → French) :

make use of diagnostic imaging procedures | use diagnostic imaging procedures | carry out diagnostic imaging procedures | perform diagnostic imaging procedures

handle venepuncture procedure equipment | use venepuncture equipment | use venepuncture procedure equipment | utilise venepuncture procedure equipment

comply with guidelines for use of hazardous substances | ensure safe use of substances hazardous to health | follow control of health procedures for hazardous substances | follow control of substances hazardous to health procedures

Air Carriers Using Small Aeroplanes Order [ Order Respecting Standards and Procedures for Air Carriers Using Small Aeroplanes in Air Transport Operations ]

Air Carriers Using Large Aeroplanes Order [ Order respecting standards and procedures for air carriers using large aeroplanes ]

Chemiluminescent ELISA involving an extraction procedure and an ELISA technique, using an enhanced chemiluminescent reagent | Enfer-Test

procedure for opening,administering and using accounts

procedure for opening, administering and using accounts

X-ray equipment in medical diagnosis part A: recommended safety procedures for installations and use - safety code 20A [ X-rays in medical, dental and paramedical diagnostic radiology - recommended installation and safety procedures ]

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include sel ...[+++]f-report data, analysis of blood and other body fluids, characteristic physical and psychological symptoms, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

(f) if the human reproductive material is used to create in vitro embryos for a third party’s reproductive use and there are in vitro embryos in excess of the third party’s reproductive needs, the excess in vitro embryos will be used in accordance with the third party’s consent and, if the use is providing instruction in assisted reproduction procedures, improving assisted reproduction procedures or other research, the consent of the donor in accordance with section 4;

(Return tabled) Question No. 1123 Ms. Kirsty Duncan: With respect to the government’s position on chronic cerebrospinal venous insufficiency (CCSVI): (a) does the government track clinical trials on CCSVI currently being undertaken by other countries and, if yes, what are all clinical trials, identified by phase, currently being undertaken worldwide, (i) which countries are undertaking Phase lll trials; (b) does the government question whether CCSVI exists and, if yes, (i) why does the government not question whether treating CCSVI actually improves quality of life for Canadians with multiple sclerosis (MS); (c) how many cases of " major complications associated with venous angioplasty" have occurred in Canada and, if it is not possible ...[+++]to give this number, why, (i) what are identified complications to CCSVI and, for each complication, how many cases versus the number of procedures undertaken have occurred; (d) what are all procedures that have been performed on veins in Canada, including, procedures for Budd-Chiari syndrome and May-Thurner syndrome; (e) what is the government's position on ballooning veins and why does it consider that ballooning veins even once could be unsafe on fragile veins, even though participants involved in the proposed clinical trial will experience two procedures-one real, one simulated-in a one-year period; (f) is the government consulting with Canadians with MS, if so, (i) provide a list of all CCSVI groups the Minister of Health has met with along with the dates of the meetings, (ii) provide a list of all MS groups the Minister of Health has met with along with the dates of the meetings, (iii) provide the number of Canadians with MS the Minister of Health has met and the dates of all meetings, and if the government is not consulting, (iv) why not; (g) how does inviting the investigators of the seven MS-funded CCSVI studies to participate in the consensus workshop on ultrasound imaging meet CIHR's conflict of interest g ...

In order to ensure uniform conditions for the implementation of this Regulation, implementing powers should be conferred on the Commission as regards laying down rules on the form of the product specification; laying down detailed rules on the form and content of the register of protected designations of origin and protected geographical indications; defining the technical characteristics of the Union symbols and indications as well as the rules on their use on products, including the appropriate linguistic versions to be used; granting and extending transitional periods for temporary derogations for use of protected designations of o ...[+++]rigin and protected geographical indication; laying down detailed rules on the form and content of the register of traditional specialities guaranteed; laying down rules for the protection of traditional specialities guaranteed; laying down all measures relating to forms, procedures and other technical details for the application of Title IV; laying down rules for the use of optional quality terms; laying down rules for the uniform protection of indications, abbreviations and symbols referring to the quality schemes; laying down detailed rules on the procedure, form and presentation of applications for registration and of oppositions; rejecting the application; deciding on the registration of a name if an agreement has not been reached; laying down detailed rules on the procedure, form and presentation of an amendment application; cancelling the registration of a protected designation of origin, a protected geographical indication or a traditional speciality guaranteed; and laying down detailed rules on the procedure and form of the cancellation process and on the presentation of the requests for cancellation.

Question No. 419 Ms. Kirsty Duncan: With respect to the risk of corrosion and spills and other safety concerns arising from the transport of bitumen in pipelines, and to government action to address these risks: (a) how does diluted bitumen compare with West Texas Intermediate (WTI) in terms of (i) abrasive material content, (ii) acid concentration, (iii) sulphur content, (iv) viscosity; (b) to what extent is diluted bitumen more likely than WTI to cause corrosion or erosion in the pipelines through which they respectively flow; (c) what is the composition of diluted bitumen in Canada; (d) what are all of the volatile chemicals, persistent organic pollutants or carcinogenic substances present in diluted bitumen in Canada; ( ...[+++]e) in the process of diluting bitumen in Canada, what are the (i) natural gas condensates used, (ii) other petroleum products used; (f) what is the process by which diluted bitumen corrodes pipelines, with specific reference to (i) abrasion, (ii) friction, (iii) high pressure, (iv) settling of sediment, (v) velocity, (vi) sulphur-reducing bacteria, (vii) other significant factors; (g) for all proposed or existing National Energy Board (NEB)-regulated pipelines, what is (i) the amount of hard sediment passing through the pipeline annually, (ii) the average pressure, (iii) the average temperature; (h) what, if any, (i) research, (ii) action, (iii) investment has the government undertaken to determine whether diluted bitumen can flow safely through pipelines; (i) what, if any, (i) research, (ii) action, (iii) investment has the government undertaken to determine whether or not conventional crude should be distinguished from diluted bitumen when setting minimum standards for pipelines; (j) what, if any, (i) research, (ii) action, (iii) investment has the government undertaken to design safety and spill responses and spill liability management capabilities that are appropriate specifically to diluted bitumen; (k) how does a diluted bitumen sp ...